Table 3 Comparison of secondary endpoints and study drug application between the argatroban- and lepirudin-group
From: Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial
Argatroban (number = 34) | Lepirudin (number = 32) | P | |
|---|---|---|---|
Secondary endpoints | |||
Bleeding (number) | 4 (12%) | 11 (34%) | 0.040 |
Moderate (number) | 2 (6%) | 8 (25%) | 0.041 |
Severe (number) | 2 (6%) | 3 (9%) | 0.667 |
Packed red blood cells (Units) | 3 ± 8 | 4 ± 5 | 0.488 |
Fresh frozen plasma (Units) | 3 ± 12 | 2 ± 5 | 0.582 |
Platelet transfusion (Units) | 1 ± 4 | 1 ± 2 | 0.949 |
Newly diagnosed thrombembolic events (number) | 3 (9%) | 2 (6%) | 0.639 |
Anaphylactoid reactions (number) | 1(3%) | 2 (6%) | 0.608a |
Length of ICU stay (days) | 24 ± 22 | 32 ± 32 | 0.213 |
Length of hospital stay (days) | 54 ± 41 | 53 ± 55 | 0.919 |
In-hospital mortality (number) | 6 (18%) | 9 (28%) | 0.389 |
Time until target aPTT of 55 to 65 seconds (hours) | 20 ± 19 | 11 ± 9 | 0.017 |
Time until aPTT ≥55 seconds (hours) | 12 ± 16 | 8 ± 6 | 0.189 |
Patients with first aPTT >65 seconds (number) | 9 (26%) | 4 (12%) | 0.213 |
First aPTT >65 seconds (seconds) | 69 ± 3 | 74 ± 10 | 0.389 |
Study drug application | |||
Duration of study drug application (hours) | 103 ± 47 | 126 ± 37 | 0.030 |
Infusion rate (ml/hour) | 4.1 ± 2.9 | 3.8 ± 2.5 | 0.654 |
Interruption in study drug application (number) | 12 (35%) | 14 (43%) | 0.615 |
Cumulative duration of interruptions (hours) | 33 ± 39 | 34 ± 39 | 0.860 |